Encomenda rápida

Text Size:AAA

DPP4 / CD26  Proteína

All DPP4 Reagents

Anfitrião da expressão: Human Cells  
  • Slide 1
10688-H08H-20
10688-H08H-10
20 µg 
10 µg 
Add to Cart
Descrição do produto: Active  
Anfitrião da expressão: Human Cells  
  • Slide 1
10688-H01H-10
10688-H01H-20
10 µg 
20 µg 
Add to Cart
Descrição do produto: Active  
Anfitrião da expressão: Human Cells  
  • Slide 1
10688-HNCH-10
10688-HNCH-20
10 µg 
20 µg 
Add to Cart
Anfitrião da expressão: Human Cells  
  • Slide 1
50718-M08H-10
50718-M08H-50
10 µg 
50 µg 
Add to Cart
Anfitrião da expressão: Human Cells  
  • Slide 1
50718-M01H-20
50718-M01H-10
20 µg 
10 µg 
Add to Cart
Anfitrião da expressão: Human Cells  
  • Slide 1
90180-C01H-10
90180-C01H-20
10 µg 
20 µg 
Add to Cart
Anfitrião da expressão: Human Cells  
  • Slide 1
90180-CNCH-10
90180-CNCH-20
10 µg 
20 µg 
Add to Cart
Anfitrião da expressão: Human Cells  
  • Slide 1
90180-C08H-10
90180-C08H-50
10 µg 
50 µg 
Add to Cart

Browse DPP4 / CD26 Products by

DPP4 / CD26 Caminhos relacionados

    DPP4 / CD26 Produtos relacionados

    DPP4 / CD26 Produtos relacionados

    Featured Reagent Products

    DPP4 / CD26 Informações relativas a proteínas e resumo

    DPP4 / CD26 Fundo

    Resumo de gene: The protein encoded by this gene is identical to adenosine deaminase complexing protein-2, and to the T-cell activation antigen CD26. It is an intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides
    General information above from NCBI
    Atividade catalítica: Release of an N-terminal dipeptide, Xaa-Yaa-|- Zaa-, from a polypeptide, preferentially when Yaa is Pro, provided Zaa is neither Pro nor hydroxyproline.
    Regulação de enzima: Inhibited by GPC3 and diprotin A.
    Estrutura da subunidade: Monomer. Homodimer or heterodimer with Seprase (FAP). Requires homodimerization for optimal dipeptidyl peptidase activity and T-cell costimulation. Found in a membrane raft complex, at least composed of BCL10, CARD11, DPP4 and IKBKB. Associates with collagen. Interacts with PTPRC; the interaction is enhanced in a interleukin-12-dependent manner in activated lymphocytes. Interacts (extracellular domain) with ADA; does not inhibit its dipeptidyl peptidase activity. Interacts with CAV1 (via the N-terminus); the interaction is direct. Interacts (via cytoplasmic tail) with CARD11 (via PDZ domain); its homodimerization is necessary for interaction with CARD11. Interacts with IGF2R; the interaction is direct. Interacts with GPC3. Interacts with human coronavirus-EMC spike protein and acts as a receptor for this virus.
    Domínio: The extracellular cysteine-rich region is necessary for association with collagen, dimer formation and optimal dipeptidyl peptidase activity.
    Localização subcelular: Dipeptidyl peptidase 4 soluble form: Secreted. Note=Detected in the serum and the seminal fluid.
    Cell membrane; Single-pass type II membrane protein. Apical cell membrane; Single-pass type II membrane protein. Cell projection, invadopodium membrane; Single-pass type II membrane protein. Cell projection, lamellipodium membrane; Single-pass type II membrane protein. Cell junction. Membrane raft. Note=Translocated to the apical membrane through the concerted action of N- and O-Glycans and its association with lipid microdomains containing cholesterol and sphingolipids. Redistributed to membrane rafts in T-cell in a interleukin-12- dependent activation. Its interaction with CAV1 is necessary for its translocation to membrane rafts. Colocalized with PTPRC in membrane rafts. Colocalized with FAP in invadopodia and lamellipodia of migratory activated endothelial cells in collagenous matrix. Colocalized with FAP on endothelial cells of capillary-like microvessels but not large vessels within invasive breast ductal carcinoma. Colocalized with ADA at the cell junction in lymphocyte-epithelial cell adhesion. Colocalized with IGF2R in internalized cytoplasmic vesicles adjacent to the cell surface.
    Especificidade do tecido: Expressed specifically in lymphatic vessels but not in blood vessels in the skin, small intestine, esophagus, ovary, breast and prostate glands. Not detected in lymphatic vessels in the lung, kidney, uterus, liver and stomach (at protein level). Expressed in the poorly differentiated crypt cells of the small intestine as well as in the mature villous cells. Expressed at very low levels in the colon.
    Indução: Up-regulated by IL12/interleukin-12 on activated T- cells. IL12-activated cells expressed enhanced levels of DPP4 but not mRNAs. Down-regulated by TNF. Up-regulated in migratory endothelial cells and in the invasive endothelial cells in tumors.
    Pós-translacional: The soluble form (Dipeptidyl peptidase 4 soluble form also named SDPP) derives from the membrane form (Dipeptidyl peptidase 4 membrane form also named MDPP) by proteolytic processing.
    N- and O-Glycosylated.
    Phosphorylated. Mannose 6-phosphate residues in the carbohydrate moiety are necessary for interaction with IGF2R in activated T-cells. Mannose 6-phosphorylation is induced during T- cell activation.
    Semelhança da sequência: Belongs to the peptidase S9B family. DPPIV subfamily.
    General information above from UniProt

    Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.

    DPP4 / CD26 Nome alternativo

    DPP4 / CD26 Estudos relacionados

  • Doupis J, et al. (2008) DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther. 25(7): 627-43.
  • Havre PA, et al. (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 13: 1634-45.
  • De Chiara L, et al. (2009) Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Dis Markers. 7(6): 311-6.
  • Matteucci E, et al. (2009) Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 16(23): 2943-51.
  • Tenha em atenção o seguinte: Todos os produtos destinam-se "A FINS EXCLUSIVOS DE INVESTIGAÇÃO E NÃO DEVEM SER UTILIZADOS PARA EFEITOS DE DIAGNÓSTICO OU TERAPÊUTICOS"